60
Participants
Start Date
October 31, 2008
Primary Completion Date
January 31, 2013
Study Completion Date
October 31, 2013
Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
"Eligible patients will receive:~* nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.~* Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.~* Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.~After completion of the above regimen, patients will receive:~* Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.~* Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.~Patients will then proceed with:~\- Surgery including axillary staging~A minimum of 4 weeks post operatively, patient will receive:~\- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses."
University of Tennessee Cancer Institute, Memphis
The West Clinic, Memphis
The Center for Cancer and Blood Disorders, Fort Worth
Collaborators (2)
National Comprehensive Cancer Network
NETWORK
Celgene Corporation
INDUSTRY
Genentech, Inc.
INDUSTRY
University of Tennessee Cancer Institute
OTHER